ClinicalTrials.gg
Status unknownNCT05105529Updated Jun 2, 2022

Adaptation to Ozone in Individuals With Asthma/Exercise-induced Bronchoconstriction

An interventional study of Exercise and Ozone in Asthma, Asthma, Exercise-Induced and Exercise Induced Asthma, sponsored by University of British Columbia. Status unknown at 2 sites in Canada. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2022-06-02.

Primary conditionAsthma, Exercise-InducedRegistry: AsthmaReclassifiedWhy we changed it
Registry
Asthma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Asthma, Exercise-Induced
Why
  1. The study's listed conditions name Asthma, Exercise-Induced, a narrower term within Asthma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of British Columbia · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2021, registered Sep 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Researchers found that impairments in the cardiopulmonary system caused by acute exposure to ozone were outweighed by repeated exposures to ozone. The goal of this study is to confirm there will be an adaptation similar to what was previously proved but in individuals with asthma and exercise-induced bronchoconstriction (EIB). The purpose is to examine adaptive responses in a randomized cross-over trial in which physically active individuals will perform submaximal exercise on five days in ozone and filtered air exposures separated by a washout period.

02

Conditions studied

  • Asthma
  • Asthma, Exercise-Induced
  • Exercise Induced Asthma
  • Exercise Induced Bronchospasm

Browse trials for

Keywords

  • Ozone
  • Air pollution
  • Asthma
  • Exercise-induced bronchoconstriction
03

In context

Asthma, Exercise-Induced Reclassified

52 studies on the registry are indexed under Asthma, Exercise-Induced; 3 are open to participants now.

This study's planned enrollment of 40 is below the median of 47 across 40 interventional studies indexed under Asthma, Exercise-Induced.

Browse Asthma, Exercise-Induced studies →

Lead sponsor

University of British Columbia is the lead sponsor of 1,339 studies on the registry; 259 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Compared within Asthma, Exercise-Induced, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Asthma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recreationally active individuals
  • Diagnosed asthma and/or mild exercise-induced bronchoconstriction: defined by an fall equal to or greater than 10% but lower than 25% in the eucapnic hyperventilatory test.
  • Able to securely perform a maximal exercise test (responded 'no' to all questions on the PAR-Q+ questionnaire)
  • Able to communicate in English

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with any cardiorespiratory or vascular diseases
  • Pregnant or potentially pregnant
  • Non-smoking
  • Lower limb musculoskeletal injury or lower limb limitation to cycle on a bicycle ergometer
  • Recent respiratory symptoms or upper tract infection within 4 weeks
  • On vitamin (e.g., C or E) supplementation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Ozone (O3) group

    Participants of the experimental group will perform sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling 170ppb ozone delivered continuously during each exercise session.

    Behavioral: Exercise · Other: Ozone

  • Sham comparator
    Filtered Air

    Participants of the sham group will also perform sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer similar to intervention. However, only in this group, the ozone generator will not be activated so that just filtered air will be delivered to the participant while performing each exercise session.

    Behavioral: Exercise · Other: Filtere Air

Interventions

  • BehavioralExercise

    Cycling at 60% of VO2max on a cycle ergometer for 30 minutes

  • OtherOzone

    Breathing 170ppb ozone

  • OtherFiltere Air

    Breathing filtered air

06

What researchers measure

Primary outcomes

  1. Change in FEV1 from baseline to 10 minutes after exercise

    Measurement of pulmonary function: forced exhaled volume in the first second (FEV1) in liters

    Time frame: Measured at baseline and 10 minutes after each exercise bout

  2. Change in FVC from baseline to 10 minutes after exercise

    Measurement of pulmonary function: forced vital capacity (FVC) in liters

    Time frame: Measured at baseline and 10 minutes after each exercise bout

  3. Change in FEF25-75 from baseline to 10 minutes after exercise

    Measurement of pulmonary function: forced expiratory flow at 25-75% of pulmonary volume in liters per second (L/s)

    Time frame: Measured at baseline and 10 minutes after each exercise bout

Secondary outcomes

  1. Change in Pulse Wave Velocity (PWV) from baseline to 20 minutes after exercise

    Velocity (in meters per second) at which the blood pressure pulse propagates through set points in the circulatory system

    Time frame: Measured at baseline and 20 minutes after each exercise bout

  2. Change in Fraction of exhaled nitric oxide (FeNO) from baseline to 5 minutes after exercise

    Non-invasive airway inflammation biomarker (in part per billion, ppb)

    Time frame: Measured at baseline and 5 minutes after each exercise bout

07

Study locations

2 of 2 sites recruiting
  • Environmental Physiology Laboratory
    Vancouver, British Columbia V6T 1Z1, Canada
    Recruiting
    • Michael Koehle, MD, PhD · Contactmichael.koehle@ubc.ca · 604 8229331
    • Michael Koehle, MD, PhD · Principal investigator
  • University of British Columbia
    Vancouver, British Columbia V6T 1Z3, Canada
    Recruiting
    • Michael Koehle, MD, PhD · Contactmichael.koehle@ubc.ca · (604) 822-9331
    • Michael Koehle, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05105529
Responsible party
Michael Koehle (Professor, University of British Columbia) — Principal investigator
First posted
Nov 3, 2021
Start date
Jan 1, 2021
Primary completion
Jan 2023 (estimated)
Completion
Feb 2023 (estimated)
Last update
Jun 2, 2022

Study contacts

Patric O Gonçalves, BScPT
Contact
patricog@alumni.ubc.ca
6048229331
Michael Koehle
Contact
michael.koehle@icloud.com
Michael Koehle, MD PhD
principal investigator · Professor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion